First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody
- Written by PR Newswire
![]() |
- COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease
- HBM9378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026
- HBM9378/WIN378 has the potential to be the first-to-market, ultra...















